Pilot investigation of psychedelic-assisted psychotherapy for treatment of post-traumatic stress disorder (PTSD) in people diagnosed with co-occurring borderline personality disorder – a controlled before-and-after study

This interventional trial (n=20) will investigate the efficacy and safety of psychedelic-assisted psychotherapy for the treatment of PTSD in individuals diagnosed with co-occurring borderline personality disorder (BPD), using MDMA (2-5x; 80+40mg).

The study, conducted by Spectrum Personality Disorder Service for Victoria, aims to assess the feasibility and acceptability of integrating MDMA-assisted psychotherapy within a public mental health service. Participants will undergo six weeks of preparatory psychotherapy sessions, followed by two to five MDMA sessions over six months.

The control group will receive the same psychotherapy without MDMA. Primary outcomes include safety, feasibility, and cost, with secondary outcomes evaluating mood, dissociation, PTSD symptoms, and overall BPD pathology. The study, approved by the Eastern Health Human Research Ethics Committee, is scheduled to begin participant enrolment in July 2024.

Topic PTSD Personality Borderline
Compound MDMA
Country Australia
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.